Chandra Leo

Chandra joined the private equity team at HBM Partners in 2007. He has been responsible for investments in over 20 private biotech, medical device and diagnostics companies in the United States and Europe, in most cases as a board member or board observer. These companies have so far generated seven NASDAQ IPOs, five M&A transactions, and five FDA-approved marketed products. He currently serves as a director on the boards or of Galecto, Gynesonics, Monte Rosa Therapeutics and Fore.

Prior to joining HBM, Chandra worked as a postdoctoral scientist at Stanford University, as a physician at the University Hospital Leipzig and as a principal at Wellington Partners Venture Capital. He earned an MD from the Freie Universität Berlin (Charité), an MAS in Medicines Development from the University of Basel and an MBA with distinction from INSEAD.